Role of pulmonary hemodynamics in determining 6-minute walk test result in atrial septal defect: an observational study

Supomo Supomo 1*, Handy Darmawan 2 and Adika Zhulhi Arjana 2

Abstract

Background: The presence of altered pulmonary hemodynamics in adult patients with atrial septal defect (ASD) is common. However, there are no observational studies which evaluate the impact of altered pulmonary hemodynamics on the 6-min walk test (6MWT) result. This study aimed to investigate the role of pulmonary hemodynamics in determining 6MWT result of patients with ASD.

Method: Forty-six consecutive adult patients with ASD were included in this study. Right heart catheterization was performed to obtain the pulmonary hemodynamics profile. Meanwhile, 6MWT was presented as high or low with cut-off point 350 m. Receiver operating characteristic (ROC) was used for analytical methods.

Result: Abnormal functional capacity was indicated by ROC result of mPAP cut-off value of > 24 mmHg (p = 0.0243; AUC = 0.681). The value of PVR > 3.42 woods unit (WU) showed high specificity in determining abnormal functional capacity (p = 0.0069; AUC = 0.713). Flow ratio with cut-off point ≤ 4.89 had the highest sensitivity (100%) (p = 0.8300; AUC = 0.520).

Conclusion: Pulmonary hemodynamics can serve as an indicator of 6MWT result in adult ASD patients with values of mPAP > 24 mmHg and PVR > 3.42 WU.

Keywords: Atrial septal defect, Cardiac catheterization, Hemodynamic, Pulmonary hypertension

Background

Atrial septal defect (ASD) is a common congenital heart disease (CHD) with 1.64 per 1000 living birth prevalence and female predominance [1]. Ninety percent of the patients were reported to survive into adulthood and 35% of them developed secondary pulmonary hypertension (PH) [2, 3], which is defined as increased mean pulmonary artery pressure (mPAP) ≥ 25 mmHg in right heart catheterization (RHC) [4].

The presence of altered pulmonary hemodynamics due to secondary PH in adult patients with ASD is associated with reduced survival and high hospital utilization [5, 6]. Previous studies had presented the impact of altered pulmonary hemodynamics due to primary PH to functional capacity of the patient, which was measured by the 6-min walk test (6MWT) [7, 8]. The 6MWT result represents the functional capacity and predicts the outcome of the patient with PH. Values of 6MWT distance less than 350 m are a predictor of worse outcome [9].

In our knowledge, there has not been any observational studies which evaluate the impact of altered pulmonary hemodynamics due to secondary PH on adult patients with ASD on the 6MWT result. We conducted this study to investigate the role of each of the components of pulmonary hemodynamics in determining the 6MWT result.

Methods

Study participants and ethical consideration

Between January 2014 and March 2017, 46 consecutive patients with ASD in Dr. Sardjito General Hospital were included in this study. The inclusion criteria were: adults above 18 years of age, who were diagnosed with ASD in Dr. Sardjito General Hospital were included in this study. The inclusion criteria were: adults above 18 years of age, who were diagnosed with ASD.
This study included subjects who had not undergone ASD closure or vasodilator therapy to decrease PAP. This study was approved by the Institutional Ethics Committee of Faculty of Medicine, Public Health and Nursing of Universitas Gadjah Mada, Indonesia and the need for individual informed consent was waived.

**Study protocols and definitions**

All of the subjects underwent RHC to obtain their pulmonary hemodynamic profile. Pulmonary hemodynamic profile components analyzed in this study were mPAP, pulmonary vascular resistance (PVR), and flow ratio. Flow ratio is defined as ratio of Qp and Qs taken from RHC data.

\[
Q_p = \frac{O_2\text{ consumption (mL/min)}}{PV\ O_2\ content (mL/L) - PA\ O_2\ content (mL/L)}
\]

\[
Q_s = \frac{O_2\text{ consumption (mL/min)}}{SA\ O_2\ content (mL/L) - PA\ O_2\ content (mL/L)}
\]

PV (pulmonary vein); PA (pulmonary artery); SAO2 (blood oxygen saturation); MVO2 (myocardial volume oxygen).

High flow ratio is defined as Qp/Qs > 2.36 [10]. The PH was diagnosed when mPAP was ≥25 mmHg in RHC.

The 6MWT was performed after RHC to obtain the information regarding the functional capacity of the patients according to American Thoracic Society guidelines [11]. It was performed indoors on a long, flat, straight, and hard surface. This test measures the distance in meters which a patient can quickly reach unassisted in 6 min. The abnormal functional capacity was defined as 6MWT distance less than 350 m. All patients were not provided supplemental oxygen while undergoing the 6MWT. Echocardiography data was used as a baseline data for further ASD evaluation.

**Statistical analysis**

Baseline characteristics of the patients are shown in Table 1. Continuous variables were presented as mean ± standard deviation (SD) and categorical variable was presented as percentage. Continuous variables with non-parametric data were presented in median. On bivariate analysis, difference between PH and non-PH is presented on Table 2. The results are considered to be significant if \( p < 0.05 \). The relationship between PH and functional capacity was analyzed using chi-square test (Table 3). In addition, correlations between each pulmonary hemodynamics component and 6MWT were analyzed using Spearman’s rank correlation test due to their non-parametric data (Fig. 1). The ROC analysis was used for analyzing capability of mPAP, PVR, and flow ratio in determining functional capacity of the patient, which was presented as binary data of normal or abnormal (Fig. 2). Statistical review of the study was performed by a biomedical statistician. The data were analyzed using Medcalc software.

**Results**

Twenty-five (54.3%) patients had PH with mean mPAP 28.91 ± 11.41 mmHg (Table 1). On bivariate analysis, there were significant differences of 6MWT and mPAP between PH and non-PH (Table 2).

| Table 1 Baseline characteristic of the patients |
|---|---|---|
| Variables | N (%) | Mean ± SD | Median (min-max) |
| PH | 25 (54.3) | | |
| Non-PH | 21 (45.7) | | |
| Systolic Pressure (mmHg) | 110 (84–150) | | |
| Diastolic Pressure (mmHg) | 70 (60–104) | | |
| Age (years)a | 33 (18–58) | | |
| mPAP (mmHg) | 28.91 ± 11.41 | | |
| PVR (WU)a | 1.90 (0.20–16.90) | | |
| Flow Ratioa | 2.93 (1.27–9.00) | | |
| 6MWT (m)a | 366 (119–800) | | |
| Oxygen Saturation (%) | 98 (88–99) | | |
| Normal 6MWT | 20 (43.5) | | |
| Abnormal 6MWT | 26 (56.5) | | |

*aNon-parametric data

| Table 2 Difference characteristic between PH and non-PH |
|---|---|---|
| Variables | PH | Non-PH | \( p \) |
| ASD diameter (mm) | 2.84 ± 0.82 | 2.47 ± 0.78 | 0.1154 |
| LA dimension (mm) | 34.52 ± 5.3 | 31.86 ± 5.03 | 0.0072 |
| RA dimension (mm)a | 48 (38–69) | 45 (30–50) | 0.0881 |
| LV dimension (mm) | 37.45 ± 5.37 | 34.55 ± 4.91 | 0.0495 |
| RV dimension (mm) | 46.3 ± 7.8 | 42.41 ± 4.15 | 0.0384 |
| mPAP (mmHg) | 36.42 ± 9.69 | 19.42 ± 4.19 | < 0.0001 |
| PVR (WU)a | 3.05 (0.99–16.90) | 1.05 (0.20–3.42) | < 0.0001 |
| Flow Ratioa | 2.70 (1.27–4.89) | 3.12 (1.50–9.00) | 0.3157 |
| 6MWT (m)a | 326 (200–462) | 391 (119–800) | 0.0119 |
| High Flow | 332.67 ± 73.76 | 357.87 ± 83.41 | 0.2288b |
| Low Flow | 373.5 (118.2–800)a | 357 ± 25.06 | | |

*aNon-parametric data; bAnalyzed by Kruskal Wallis

| Table 3 Relationship between PH and functional capacity of the patient |
|---|---|---|
| Variables | Abnormal functional capacity (6MWT < 350 m) | Normal functional capacity (6MWT ≥ 350 m) | \( p \) |
| PH | 15 | 10 | 0.0302 |
| Non-PH | 5 | 16 | |
Distance between PH and non-PH patients with \( p = 0.0119 \) (Table 2). Mann Whitney analysis on 6MWT for high flow ratio and low ratio group showed a significant result \( (p = 0.048) \). Kruskal Wallis analysis for all flow ratio group showed no significant result.

Relationship between PH and abnormal functional capacity of the patient was significant in chi-square analysis with \( p = 0.0302 \) (Table 3). Figure 1 shows the correlations between pulmonary hemodynamics and 6MWT distance. Increased mPAP and pulmonary vascular resistance (PVR) were significantly correlated with decline in 6MWT distance \( (p = 0.0238 \) and \( 0.0212 \), respectively). However, the correlation between increased flow ratio and declined 6MWT distance was not significant \( (p = 0.9850) \).

ROC analysis results are shown in Fig. 2. The mPAP cut-off value of > 24 mmHg had 63% of specificity and 75% of sensitivity in determining abnormal functional capacity \( (p = 0.0243; \ \text{AUC} = 0.681) \). The value of PVR > 3.42 woods unit (WU) was shown to have 88.9% of specificity and 47.4% of sensitivity in determining abnormal functional capacity \( (p = 0.0069; \ \text{AUC} = 0.713) \). Flow ratio had the highest sensitivity (100%) in determining abnormal functional capacity with cut-off point ≤4.89. However, this result was not significant \( (p = 0.8300; \ \text{AUC} = 0.520) \) and had a very low specificity (11.11%).

**Discussion**

In adult patients with ASD, the presence of PH was reported to have association with high mortality and hospital utilization \([5, 6]\). The presence of PH itself is determined using the value of mPAP, which is one of the pulmonary hemodynamic components. The value of mPAP ≥25 mmHg is defined as PH \([4]\). However, whether this abnormal value also correlates with
functional limitation of the patient or not has previously not been studied. This study strengthens the link between altered pulmonary hemodynamics and functional capacity in adult patients with ASD.

This study used 6MWT as an indicator of functional capacity. Earlier studies showed that 6MWT could substitute cardiopulmonary exercise testing to measure functional capacity in low resource setting [12–14]. Several studies demonstrated the impact of altered pulmonary hemodynamics on functional capacity of the patient, which was determined using 6MWT [7, 8]. Minai et al. [7] found that patients with PH had significantly lower 6MWT compared to non-PH patients and mPAP was the best predictor of declined 6MWT distance in multivariate analysis. On the other hand, Miyamoto et al. [8] found that 6MWT significantly correlated with PVR, but was not significantly correlated with mPAP. These studies were conducted in patients with unexplained or primary PH.

In the case of altered pulmonary hemodynamics in secondary PH due to ASD, our study showed significant difference in 6MWT distance between PH and non-PH patients (Table 2). After 6MWT distance was divided into normal and abnormal functional capacity, chi-square analysis also revealed a significant relationship between those variables (Table 3). Both increased mPAP and PVR were significantly correlated with declined 6MWT distance (Fig. 1). These results demonstrated that altered pulmonary hemodynamics have an impact on functional capacity of the adult patients with ASD.

Significant difference of 6MWT results between high and low flow ratio PH patients showed that functional capacity is correlated with shunt severity. Results from ROC analysis showed flow ratio of pulmonary to systemic circulation had the highest sensitivity (100%) in determining abnormal functional capacity, but this result was not significant and had a very low specificity (11.1%).

In addition, this study also analyzed the capability of each of the pulmonary hemodynamic components in determining abnormal functional capacity of the patients using ROC analysis. Significant result was shown by mPAP and PVR. The value of mPAP > 24 mmHg (sensitivity 75%, specificity 63%) and PVR > 3.42 WU (sensitivity 47.4%, specificity 88.9%) were determined to be predictors of this abnormal condition (Fig. 2).

Limitations

Our study has the limitation of using a cross-sectional design, which only provides the outcome and factors associated to it at a specific point of time. In addition, patients included in this study were only adult ASD patients with more than 18 years of age. Therefore, the results of this study may not be applicable for pediatric ASD patients.

Conclusion

The presence of altered pulmonary hemodynamic on secondary PH due to ASD in adult patients is associated with abnormal functional capacity. Values of mPAP > 24 mmHg and PVR > 3.42 WU were found to be indicators of this abnormal condition.

Abbreviations

6MWT: 6-min walk test; ASD: Atrial septal defect; CHD: Congenital heart disease; mPAP: Mean pulmonary artery pressure; PH: Pulmonary hypertension; PVR: Pulmonary vascular resistance; RHC: Right heart catheterization; SD: Standard deviation.

Acknowledgements

The authors give thanks to all ASD patients in Dr. Sardjito General hospital, who participated in this study.

Funding

This study used authors’ personal funds.

Authors’ contributions

S, HD, and AZA contributed to study conception and design; HD and AZA contributed to data acquisition, analysis, and interpretation; S and HD contributed to article writing; S, HD, and AZA contributed to editing, reviewing, and final approving of article.

Ethics approval and consent to participate

The study was reviewed and approved by the Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada Institutional Review Board. The need for individual informed consent was waived by Institutional Review Board of Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1Department of Thoracic and Cardiovascular Surgery, Dr. Sardjito General Hospital, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Kesehatan St, Number 1, Sleman, Yogyakarta 55281, Indonesia.

2Department of Thoracic and Cardiovascular Surgery, St Elizabeth Hospital, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Kesehatan St, Number 1, Sleman, Yogyakarta 55281, Indonesia.

3Department of Thoracic and Cardiovascular Surgery, Dr. Sardjito General Hospital, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Kesehatan St, Number 1, Sleman, Yogyakarta 55281, Indonesia.

Received: 3 October 2017 Accepted: 9 May 2018
Published online: 22 May 2018

References

1. Van Der Linde D, Konings EM, Slager MA, Witsenburg M, Helbing WA, Takkenberg JIM, Roos-Hesselink JW. Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis. J Am Coll Cardiol. 2011;58:2241–7 PMID: 22078432. https://doi.org/10.1016/j.jacc.2011.08.025.

2. Kuijpers J, Mulder BJM, Bouma BJ. Secundum atrial septal defect in adults: a practical review and recent developments. Neth Heart J. 2015;23:205–11 PMID: 25884091. https://doi.org/10.1007/s12471-015-0663-z.

3. Engelfriet P, Meijboom F, Boersma E, Tijssen J, Mulder B. Repaired and open atrial septal defect type II in adulthood: an epidemiological study of a large european cohort. Int J Cardiol. 2008;126:379–85 PMID: 17586067. https://doi.org/10.1016/j.ijcard.2007.04.044.

4. Badesch DB, Champion HC, Sanchez MAG, Hoeper MM, Loyd JE, Manes A, McGoon M, Naeije R, Olschewski H, Oudiz RJ, Torbicki A. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54: s55–66 PMID: 19555859. https://doi.org/10.1016/j.jacc.2009.04.011.

5. Lowe BS, Therrien J, Ionescu-Ittu R, Pilote L, Martucci G, Marelli AJ. Diagnosis of pulmonary hypertension in the congenital heart disease adult
6. Rodriguez FH 3rd, Moodie DS, Parekh DR, Franklin WJ, Morales DL, Zafar F, Graves DE, Friedman RA, Rossano JW. Outcomes of hospitalization in adults in the United States with atrial septal defect, ventricular septal defect, and atioventricular septal defect. Am J Cardiol. 2011;108:290–3 PMID: 21545985. https://doi.org/10.1016/j.amjcard.2011.03.036.

7. Minai OA, Santacruz JF, Alster JM, Budev MM, McCarthy K. Impact of pulmonary hemodynamics on 6-min walk test in idiopathic pulmonary fibrosis. Respir Med. 2012;106:1613–21 PMID: 22902266. https://doi.org/10.1016/j.rmed.2012.07.013.

8. Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita M, Nakanishi N, Miyatake K. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Am J Respir Crit Care Med. 2000;161:487–92 PMID: 10673190. https://doi.org/10.1164/ajrccm.161.2.9906015.

9. Lai YC, Potoka KC, Champion HC, Mora AL, Gladwin MT. Pulmonary arterial hypertension: the clinical syndrome. Circ Res. 2014;115:115–30 PMID: 24951762. https://doi.org/10.1161/CIRCRESAHA.115.301146.

10. Farouk A, Algowhary M, Hassan MH, et al. Circulating B-type natriuretic peptide levels and its correlation to Qp/Qs ratio among children undergoing congenital heart surgery. J Egypt Soc Cardio-Thoracic Surg. 2017;25(1):58–63. https://doi.org/10.1016/j.jescts.2017.03.002.

11. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166:111–7 PMID: 12091180. https://doi.org/10.1164/ajrccm.166.1.at1102.

12. de Assis Ramos R, Guimarães FS, Dionyssiotis Y, Tsekoura D, Papathanasiou J, de Sá Ferreira A. Development of a multivariate model of the six-minute walked distance to predict functional exercise capacity in hypertension. J Bodyw Mov Ther. 2018;1:1–7. https://doi.org/10.1016/j.jbmt.2018.01.010.

13. Omar HR, Guglin M. The longitudinal relationship between six-minute walk test and cardiopulmonary exercise testing, and association with symptoms in systolic heart failure: analysis from the ESCAPE trial. Eur J Intern Med. 2017;40:e26–8. https://doi.org/10.1016/j.ejim.2016.12.017.

14. Burr JF, Bredin SSD, Faktor MD, Waburton DER. The 6-minute walk test as a predictor of objectively measured aerobic fitness in healthy working-aged adults. Phys Sports Med. 2011;39(2):133–9. https://doi.org/10.3810/psm.2011.05.1904.